Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Natera Inc. Common Stock — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $3.1 (market cap $88.87M), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 641.7× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Natera Inc. Common Stock for 0 Days on average.
| MSTZ | NTRA | |
|---|---|---|
Market Cap | $88.87M | $57.03B |
Volume | 52,792,380 | 1,131,157 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $425.64 |
52-Week Low | $2.29 | $179.42 |
Typical Hold Time | 8 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.69 with minimal daily movement (+0.37%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The stock lacks available fundamental data for key valuation and profitability metrics, creating uncertainty about its financial health. Recent ETF coverage highlights performance trends but provides limited company-specific insights.
The outlook remains uncertain due to missing financial data and bearish technical signals. Investment opportunity hinges on future earnings visibility and improved technical momentum. Key risks include lack of financial transparency and weak technical positioning that could pressure the stock toward support levels near $2.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
